Proteonomix, Inc. (OTCPK:PROT)
PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin. PROT develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology. PROT is also involved in the operation of retail Web site, Proteoderm.com to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue. In addition, PROT develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration. Further, PROT is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.
PROT, a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC towards implementing operations in the U.A.E.
PROT is the majority shareholder in XGen with the balance held by an anonymous investor group. PROT personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting PROT personnel on Jumeira 2.
During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries. XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.
It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with PROT cellular material. Discussions are now further encompassing both the construction of XGen's own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of PROT's proprietary cellular materials for treatment of disease.
To learn more about PROT visit: http://www.proteonomix.com
Landry's Restaurants, Inc. (NYSE:LNY)
LNY, recently reported its results for the second quarter ended June 30, 2010.
Revenues from continuing operations for the three months ended June 30, 2010, totaled $294.6 million, as compared to $282.0 million a year earlier. Revenues from the restaurant and hospitality group were $236.9 million for the second quarter of 2010 and $225.5 million for the comparable period in 2009, gaming revenues from the Golden Nugget properties were $57.7 million in 2010 versus $56.5 million in 2009 for the same periods. Net earnings (loss) for the quarter was ($14.1) million, compared to $6.6 million reported last year.
LNY operates as a diversified restaurant, hospitality, and entertainment company. LNY principally engages in the ownership and operation of full-service, specialty location restaurants. As of December 31, 2009, the company operated 174 restaurants, various limited menu restaurants, and other properties in 27 states and Canada. In addition, LNY owns and operates Golden Nugget Hotels and Casinos in Las Vegas & Laughlin, Nevada. LNY was founded in 1980 and is based in Houston, Texas.
To learn more about LNY visit: http://www.landrysrestaurants.com
Landstar System, Inc., (Nasdaq:LSTR)
LSTR a non-asset based provider of integrated supply chain solutions delivering safe, specialized transportation, warehousing and logistics services, earlier this month participated in Morgan Keegan's 2010 Industrial/Transportation Conference at the Drake Hotel in Chicago, Illinois. LSTR Chairman, President & CEO, Henry Gerkens presented an overview of LSTR, including its variable cost non-asset-based business model, and provided an update with respect to the current level of business activity.
LSTR operates as a non-asset based provider of freight transportation services and supply chain solutions. LSTR operates in two segments, Transportation Logistics and Insurance. LSTR provides services to shippers principally in the United States and Canada; between the United States, Canada, and Mexico; and internationally. LSTR was founded in 1968 and is headquartered in Jacksonville, Florida.
To learn more about LSTR visit: http://www.landstar.com
Lannett Company, Inc. (AMEX:LCI)
LCI announced that it purchased 1,270 shares of its common stock in the open market under LCI’s stock repurchase program. Under the program, LCI is authorized to repurchase up to $5 million of LCI’s outstanding common stock from time to time in open market and privately negotiated transactions.
“We are confident in the future of our company and believe that at current prices Lannett shares represent an attractive long term investment for the company and its shareholders,” said Arthur Bedrosian, president and chief executive officer of LCI.
LCI develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. LCI manufactures and/or sells various prescription products. LCI sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. LCI was founded in 1942 and is based in Philadelphia, Pennsylvania.
To learn more about LCI visit: http://www.lannett.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)